6,206 results match your criteria: "CNRS-Université Paris 7[Affiliation]"

Background: Data on risks and benefits of long-term anticoagulants in patients with a life-limiting disease are limited. This cohort study aims to describe (dis)continuation of anticoagulants and incidences of bleeding and thromboembolic events in vitamin K antagonist (VKA) users with a life-limiting disease.

Methods: Data from five Dutch anticoagulation clinics were linked to data from Statistics Netherlands and the Netherlands Cancer registry.

View Article and Find Full Text PDF

FGF21 Signaling Exerts Anti-Fibrotic Properties During Pulmonary Fibrosis.

Am J Respir Crit Care Med

December 2024

Université Paris Cité, Inserm, PHERE, Faculté de Médecine Paris 7, site X. Bichat, Paris, France;

Rationale: Idiopathic Pulmonary Fibrosis (IPF) is a lethal disease with limited therapeutic options. FGF21, an endocrine fibroblast growth factor that acts through the FGFR1/KLB pathway, mitigates liver fibrosis.

Objectives: We hypothesized that FGF21 could exert anti-fibrotic properties in the lung.

View Article and Find Full Text PDF

Introduction: Small full-thickness macular holes (FTMHs) are classically treated surgically but can also occasionally close spontaneously. Long-term visual outcomes of spontaneously closed FTMHs are not well described. We compared best-corrected visual acuity (BCVA) after surgical and spontaneous closure of idiopathic FTMH (IMHs) and assessed the effect of IMH size on BCVA.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to determine if severe traumatic rhabdomyolysis (with CK levels > 5000 U/L) affects the likelihood of death within 30 days for trauma patients, utilizing a causal inference approach in a multicenter cohort in France.
  • - An analysis of 8592 patients revealed that 18% had severe RM, primarily affecting young males with blunt trauma, yet it did not significantly impact overall 30-day mortality rates despite associated complications.
  • - While patients with severe RM had higher rates of multiorgan failure and septic shock during ICU stays, this risk was not a significant predictor of death when adjusted for confounding factors.
View Article and Find Full Text PDF

Low-dose IL-2 in birch pollen allergy: A phase-2 randomized double-blind placebo-controlled trial.

J Allergy Clin Immunol

November 2024

Biotherapy Clinical Investigation Center (CIC-BTi) and Inflammation-Immunopathology-Immunotherapy Department (i2B), Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Immunology-Immunopathology-Immunotherapy, Sorbonne Université, INSERM, UMR_S 959, Paris, France. Electronic address:

Background: Regulatory T (Treg) cells are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2) activates Treg cells.

Objective: Our aim was to assess IL-2 efficacy for controlling clinical responses to allergen exposures.

View Article and Find Full Text PDF

Crossed effects of helminth infection and lead exposure on fitness: An experimental study in feral pigeons (Columba livia).

J Anim Ecol

December 2024

Sorbonne Université, UPEC, Paris 7, CNRS, INRA, IRD, UMR 7618, Institut d'Ecologie et des Sciences de l'Environnement de Paris, Paris, France.

Living organisms are exposed to multiple environmental factors that can affect their fitness. The negative effects of these simultaneous stressors can be additive or can interact in negative synergistic or antagonistic ways to affect the health of exposed individuals. Parasites can accumulate pollutants in their own tissues and have been shown to increase the tolerance of their hosts to different pollutants (antagonistic interaction between parasites and pollutants).

View Article and Find Full Text PDF

CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on MRD and long-term clinical outcome using CPX-351 in AML in real-life. We retrospectively collected data from 168 patients in 36 centers in France and Italy who had received one or two cycles of induction with CPX-351.

View Article and Find Full Text PDF

Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.

Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).

View Article and Find Full Text PDF

Rnf111 has a pivotal role in regulating development of definitive hematopoietic stem and progenitor cells through the Smad2/3-Gcsfr/NO axis in zebrafish.

Haematologica

October 2024

CNRS IRP (International research Project), Cancer, Aging and Hematology, Sino-French Research Center for Life Sciences and Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Université de Paris 7/INSERM/CNRS UMR 944/7212, Equipe Labellisée Ligue Nationale Contre le Cancer, Hôpital St. Louis, Paris 75010.

Article Synopsis
  • The study investigates the role of RNF111, a ubiquitin ligase, in hematopoiesis and its influence on hematopoietic stem and progenitor cells (HSPC).
  • Researchers created a mutant zebrafish line with a knockout of Rnf111, which revealed impaired HSPC development associated with decreased Smad2/3 phosphorylation.
  • The findings suggest that RNF111 is crucial for HSPC development by regulating Smad2/3 phosphorylation and activating the Gcsfr/NO signaling pathway.
View Article and Find Full Text PDF
Article Synopsis
  • * Sugammadex can reverse the effects of rocuronium-induced neuromuscular blockade but may also provoke anaphylaxis, indicating a need for better treatment options.
  • * Research into the antibodies of patients with rocuronium sensitivity found a diverse range that can activate anaphylaxis; high-affinity antibodies capable of reversing rocuronium effects were isolated, suggesting new avenues for diagnosis and treatment.
View Article and Find Full Text PDF

Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.

Brain Behav Immun

January 2025

Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3), F-75651 Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), F-75651 Paris, France. Electronic address:

Article Synopsis
  • Scientists noticed that people with bipolar disorder, especially when they're sad, have problems with their immune system.
  • In a study, they tested a medicine called IL-2 to see if it could help these people's moods by boosting a specific part of their immune system.
  • The results showed that the IL-2 treatment was safe and helped improve mood in patients with bipolar depression.
View Article and Find Full Text PDF

Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial.

Circulation

November 2024

ACTION Study Group, INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne Université (P.G., M.L., T.R., Y.T., M.E.G., D.B., J.S., N.H., G.D., G.M.), Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.

Background: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure.

Methods: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design).

View Article and Find Full Text PDF

The GETAID: 40 years of a family story in IBD.

J Crohns Colitis

August 2024

Department of Gastroenterology, Brabois Hospital, Nancy University, Nancy les Vandoeuvre-lès-Nancy, France.

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor R Modigliani and colleagues. From the beginning, the aim of this international (France, Belgium and Switzerland), multicentre, French-speaking group was to address clinical questions raised by patients or physicians in their daily practice or the inflammatory bowel diseases community, by focusing on clinical research on treatments through randomised controlled trials, prospective cohorts and cross-sectional studies, quantifying the severity of various facets of the disease when necessary for these studies. This approach very innovative has contributed to the advancement of knowledge in inflammatory bowel diseases by publishing more than 120 original articles in peer-reviewed journals throughout the GETAID 40-year history, most of them in top publications in gastroenterology and hepatology journals.

View Article and Find Full Text PDF

Background: Implementation of goal-directed fluid therapy (GDFT) protocols remains low. Protocol compliance among anesthesiologists tends to be suboptimal owing to the high workload and the attention required for implementation. The assisted fluid management (AFM) system is a novel decision support tool designed to help clinicians apply GDFT protocols.

View Article and Find Full Text PDF

As species adapt to climatic changes, temperature-dependent functions of p53 in development, metabolism and cancer will adapt as well. Structural analyses of p53 epitopes interacting in response to environmental stressors, such as heat, may uncover physiologically relevant functions of p53 in cell regulation and genomic adaptations. Here we explore the multiple p53 elephant paradigm with an experimentally validated in silico model showing that under heat stress some p53 copies escape negative regulation by the MDM2 E3 ubiquitin ligase.

View Article and Find Full Text PDF

Wnt/β-Catenin-Activated Nonpilomatrical Carcinoma of the Skin: A Case Series.

Mod Pathol

November 2024

Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; "Biologie des infections à polyomavirus" Team, UMR INRA ISP 1282, Université de Tours, Tours, France.

Article Synopsis
  • The study investigates 16 primary cutaneous carcinomas with mutations in genes that activate the Wnt/β-catenin pathway, noting that these tumors lack matrical differentiation, which is typically associated with such mutations.
  • The tumors predominantly affected elderly patients, with a median age of 80, and were mainly located on the head, neck, and upper limbs, leading to metastatic cases in some patients.
  • Key findings include poor differentiation in tumor structure, distinct immunohistochemical profiles, and recurrent mutations in APC and CTNNB1, indicating that these tumors represent a unique group apart from other established skin tumor types.
View Article and Find Full Text PDF

Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. In this Article, we report the results of the primary analysis of the trial.

Methods: COMMANDS is a phase 3, open-label, randomised, controlled trial conducted at 142 sites in 26 countries.

View Article and Find Full Text PDF

Enhancing sepsis biomarker development: key considerations from public and private perspectives.

Crit Care

July 2024

Medical-Surgical Intensive Care Unit, Réanimation Polyvalente, Dupuytren University Hospital, CHU de Limoges, 2 Avenue Martin Luther King, 87042, Limoges Cedex, France.

Implementation of biomarkers in sepsis and septic shock in emergency situations, remains highly challenging. This viewpoint arose from a public-private 3-day workshop aiming to facilitate the transition of sepsis biomarkers into clinical practice. The authors consist of international academic researchers and clinician-scientists and industry experts who gathered (i) to identify current obstacles impeding biomarker research in sepsis, (ii) to outline the important milestones of the critical path of biomarker development and (iii) to discuss novel avenues in biomarker discovery and implementation.

View Article and Find Full Text PDF

Creg1 Regulates Erythroid Development via TGF-β/Smad2-Klf1 Axis in Zebrafish.

Adv Sci (Weinh)

September 2024

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Understanding the regulation of normal erythroid development will help to develop new potential therapeutic strategies for disorders of the erythroid lineage. Cellular repressor of E1A-stimulated genes 1 (CREG1) is a glycoprotein that has been implicated in the regulation of tissue homeostasis. However, its role in erythropoiesis remains largely undefined.

View Article and Find Full Text PDF

Diffusion enhancement and autoparametric resonance.

Phys Rev E

May 2024

Laboratoire "Matière et Systèmes Complexes" (MSC), UMR 7057 CNRS, Université Paris-Diderot (Paris 7), 75205 Paris Cedex 13, France.

The possibility of an autoparametric resonance in an isolated many-particle system induces a specific behavior of the particles in the presence of thermal noise. In particular, the variance associated with a resonant mode, and consequently that of the associated particles, is strongly increased compared to what it would have in the absence of parametric resonance. In this paper we consider a dimer submitted to a periodic potential for which there are only two modes, the center of mass motion and the internal vibration mode.

View Article and Find Full Text PDF

Background: After idiopathic epiretinal membrane (iERM) removal, it is unclear whether the internal limiting membrane (ILM) should be removed. The objective was to assess if active ILM peeling after iERM removal could induce microscotomas.

Methods: The PEELING study is a national randomised clinical trial.

View Article and Find Full Text PDF

Purpose: Rare cancers constitute over 20% of human neoplasms, often affecting patients with unmet medical needs. The development of effective classification and prognostication systems is crucial to improve the decision-making process and drive innovative treatment strategies. We have created and implemented MOSAIC, an artificial intelligence (AI)-based framework designed for multimodal analysis, classification, and personalized prognostic assessment in rare cancers.

View Article and Find Full Text PDF

[Cutaneous adnexal tumours: Development and synthesis of diagnostic fusion genes].

Ann Pathol

January 2025

CARADERM Network, Lille, France; Department of Pathology, Timone University Hospital, Marseille, France.

Cutaneous adnexal tumours are a heterogeneous group of epithelial lesions that includes tumours with follicular, sudoral and/or sebaceous differentiation, or even several combined lines of differentiation. Over the last few years, molecular analysis of these lesions has allowed to identify specific molecular events responsible for tumour development in an increasing number of tumour types. Like other rare neoplasms, such as soft tissue tumours, adnexal tumours display fusion genes resulting from chromosomal translocations that may be specific for the diagnosis if molecular data are properly integrated in the clinical and morphological setting.

View Article and Find Full Text PDF

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.

Crit Rev Oncol Hematol

August 2024

Service de Pharmacologie, Département de Biologie et Pathologie médicales, Gustave Roussy, Villejuif 94805, France; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Electronic address:

Real-life populations are more heterogeneous than those included in prospective clinical studies. In cancer patients, comorbidities and co-medications favor the appearance of severe adverse effects which can significantly impact quality of life and treatment effectiveness. Most of tyrosine kinase inhibitors (TKI) have been developed with flat oral dosing exposing patients to the risk of poor adherence due to side effects.

View Article and Find Full Text PDF